Methods for treating B-cell malignancies such as relapsed and/or refractory B-cell malignancies with a population of genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting CD19 and having multiple genetic edits, including a disrupted TRAC gene, a disrupted ?2M gene, a disrupted Regnase 1 gene, and/or a disrupted TGFBRII gene.

The present disclosure pertains to a GUCY2C-binding polypeptide and uses thereof and, specifically, to a GUCY2C-binding polypeptide, a fusion protein including same, a chimeric antigen receptor, an immune cell expressing the chimeric antigen receptor, and a use thereof for treatment and/or diagnosis of cancer.

Ani-CD20 antibodies (e.g., UniAbs?) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD20.

Provided herein are, among other things, methods for treating a patient suffering from a CD38+ cancer.

In one aspect, a method generally includes obtaining a dried silicified cell that has been stored for at least 24 hours without cryopreservation and rehydrating the dried silicified cell in a pharmaceutically acceptable carrier. The method can further include surface modifying the silicified cell with at least one immunogenic molecule. The method can further include administering the rehydrated silicified cell to a subject. In some embodiment, the dried silicified cell has been stored for at least 14 days without cryopreservation. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject a chemotherapeutic agent effective to treat the tumor and administering to the subject a silicified cell vaccine effective to treat the tumor.

Disclosed herein are fibroblast activation protein (FAP)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and/or CARs for the treatment of, for example, a cancer.

Methods of use of early apoptotic cell populations and compositions thereof disclosed herein, including methods of treating a cancer or a tumor, extending survival times of a subject suffering from a cancer or a tumor, and reducing the size or reducing the growth rate of a cancer or a tumor, wherein subjects are administered apoptotic cells or compositions thereof. Cancers may include solid tumors or diffuse cancers, for example leukemia. In certain instances compositions may include additional chemotherapeutic agent. Further, inactivated early apoptotic cell populations are disclosed and methods of making the same.

Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

The present disclosure relates to compositions comprising isolated T cells, with activity against a fungal antigen, a viral antigen or a tumour antigen, wherein the composition comprises a defined number or defined ratio of T cells. Described herein are compositions comprising at least two populations of T cells, the compositions being suitable for treating various diseases and disorders.

The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.